Nchi: Kanada
Lugha: Kifaransa
Chanzo: Health Canada
Méropénem
PFIZER CANADA ULC
J01DH02
MEROPENEM
1G
Poudre pour solution
Méropénem 1G
Intraveineuse
30ML
Prescription
CARBAPENEMS
Numéro de groupe d'ingrédients actifs (GIA) :0128599002; AHFS:
COMMERCIALISÉ
2001-07-16
Page 1 of 41 PRODUCT MONOGRAPH MERREM Meropenem for injection, 500 mg, 1 g per vial (as meropenem trihydrate) For intravenous use Antibiotic Pfizer Canada ULC 17 300 Trans-Canada Highway Kirkland, Québec H9J 2M5 Date of Revision: April 8, 2019 Submission Control No: 222507 ® Pfizer Ireland Pharmaceuticals Pfizer Canada ULC, Licensee © Pfizer Canada ULC 2019 Page 2 of 41 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION....................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................... 3 CONTRAINDICATIONS ................................................................................................ 5 WARNINGS AND PRECAUTIONS............................................................................... 5 ADVERSE REACTIONS ................................................................................................ 9 DRUG INTERACTIONS ............................................................................................... 12 DOSAGE AND ADMINISTRATION ........................................................................... 13 OVERDOSAGE ............................................................................................................. 17 ACTION AND CLINICAL PHARMACOLOGY ......................................................... 17 STORAGE AND STABILITY....................................................................................... 25 DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................... 26 PART II: SCIENTIFIC INFORMATION ............................................................................ 27 PHARMACEUTICAL INFORMATION ...................................................................... 27 CLINICAL TRIALS ....................................................................................................... 27 DETAILED PHARMACOLOGY .......... Soma hati kamili